

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/011427-2024>

Contract

NHS Devon - Medicines Optimisation Services

NHS Devon Integrated Care Board

F03: Contract award notice

Notice identifier: 2024/S 000-011427

Procurement identifier (OCID): ocids-h6vhtk-0450a2

Published 9 April 2024, 12:11pm

Section I: Contracting authority

I.1) Name and addresses

NHS Devon Integrated Care Board

Aperture House, Pynes Hill, Rydon Lane

Exeter

EX2 5AZ

Email

scwcsu.clinical.procurement@nhs.net

Country

United Kingdom

Region code

UKK4 - Devon

Justification for not providing organisation identifier

Not on any register

Internet address(es)

Main address

<https://onedevon.org.uk/>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Devon - Medicines Optimisation Services

II.1.2) Main CPV code

- 85149000 - Pharmacy services

II.1.3) Type of contract

Services

II.1.4) Short description

The subscription to the Medicines Optimisation Service will provide a comprehensive set of resources to support the medicines optimisation cost improvement programmes and to further support the implementation of key medicines optimisation priorities for NHS Devon.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £96,854

II.2) Description

II.2.3) Place of performance

NUTS codes

- UKK4 - Devon

II.2.4) Description of the procurement

The subscription to the Medicines Optimisation Service provides a comprehensive set of resources to support the medicines optimisation cost improvement programmes and to further support the implementation of key medicines optimisation priorities for NHS Devon.

The Medicines Optimisation Service supports NHS commissioners to improve patient outcomes and manage medicines budgets effectively. It also supports collaboration across the NHS and therefore reduces duplication.

NHS Devon is looking to award a Medicines Optimisation Service to PrescQIPP, the incumbent provider, using the Direct Award C process under the Health Care Services (Provider Selection Regime) Regulations 2023 (the 'Regulations').

The subscription to Medicines Optimisation Services for NHS Devon is considered a Pharmacy Service and is subject to the Regulations that came into force on 1st January 2024.

The contract will be for a 2-year period with the option to extend for a further 1-year period. The total value of the contract including the extension period is £96,854 (excl VAT).

This procurement has been carried out by NHS South, Central and West Commissioning Support Unit (SCW) on behalf of the Commissioners.

II.2.5) Award criteria

Quality criterion - Name: Quality and Innovation / Weighting: 30%

Quality criterion - Name: Integration, collaboration and service sustainability / Weighting:

10%

Quality criterion - Name: Improving access, reducing health inequalities and facilitating choice / Weighting: 10%

Quality criterion - Name: Social Value / Weighting: 10%

Cost criterion - Name: Value / Weighting: 40%

II.2.11) Information about options

Options: Yes

Description of options

The contract will be for a 2-year period with the option to extend for a further 1-year period.

II.2.14) Additional information

The existing provider is satisfying the original contract and will likely satisfy the proposed contract to a sufficient standard.

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The procurement falls outside the scope of application of the regulations

Explanation:

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority via the email address scwcsu.clinical.procurement@nhs.net by midnight (23:59) on 19/4/2024. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract

Title

Subscription to Medicines Optimisation Services

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

28 March 2024

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

PrescQIPP C.I.C

Murray Harcourt, 6 Queen Street,

Leeds

LS1 2TW

Country

United Kingdom

NUTS code

- UKE42 - Leeds

Companies House

09814012

The contractor is an SME

Yes

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £96,854

Total value of the contract/lot: £96,854

Section VI. Complementary information

VI.3) Additional information

This is a Provider Selection Regime (PSR) intention to award notice (via Direct Award C). The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be submitted to the relevant authority via the email address scwcsu.clinical.procurement@nhs.net by midnight (23:59) on 19/4/2024.

This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Decision Makers:

NHS Devon Senior Leadership Team

NHS Devon Primary Care Medicines Optimisation Group

Approval was granted on 11th January 2024 via a Procurement Approach Record signed by the Head of Contracting to ensure compliance with NHS Devon's procurement policy.

The Key Criteria and Evaluation Methodology was reviewed by the NHS Devon Senior Leadership Team on 23rd February 2024 and approved by the Primary Care Medicines Optimisation Group on 28th February 2024.

The scoring of current and likely future performance of the contract was reviewed by the NHS Devon Senior Leadership Team on 21st March 2024 and approved by the Primary Care Medicines Optimisation Group on 27th March 2024.

The Decision Making record was approved by the NHS Devon Head of Contracting on 28th March 2024.

No conflicts of interest were declared.

NHS Devon considered the five key criteria as stated in the Regulations when applying Direct Award Process C and authorised the following weightings on 28th February 2024:

- Quality and Innovation (30%)
- Value (40%)

- Integration, collaboration and service sustainability (10%)
- Improving access, reducing health inequalities and facilitating choice (10%)
- Social Value (10%)

The value criteria was weighted heaviest to recognise the importance of the return on investment that a Medicines Optimisation Service realises through prescribing cost savings and rebates achieved, the tangible impact made to the management of medicines budgets and the saving made in relation to staff time.

Quality and Innovation was weighted the second highest due to the requirement to have a service that results in increased quality and innovation for NHS Devon.

The other criteria were weighted equally at 10%.

The Integration, collaboration and service sustainability criteria ensured consideration of the ICB, GP practices, Community Pharmacists, Primary Care Networks, Acute, Community and Mental Health Trusts, and care homes. With prescribing being the second highest area of expenditure in the NHS, the provider has to have a positive impact on the financial sustainability of prescribing.

The Improving access, reducing health inequalities and facilitating choice criteria looked at effective contributions to safe and effective treatments being prescribed to patients and improving outcomes.

Social value was considered with assessment of policies and practices aligning with moving towards net zero and supporting broader social, environmental, and economic development.

The incumbent provider was assessed against these key criteria in relation to current performance against the existing contract and likely future performance of the contract.

The incumbent provider has been satisfying the existing contract to a sufficient standard and has provided excellent return on investment, demonstrated excellent quality control to provide resources with the necessary evidence base with suitably qualified and experienced individuals in place.

The provider has a workplan with a number of projects to be delivered over the next three years. The quality assurance process will remain the same and further efficiency savings have been projected.

VI.4) Procedures for review

VI.4.1) Review body

NHS Devon Integrated Care Board

Aperture House, Pynes Hill, Rydon Lane, Devon

Exeter

EX2 5AZ

Country

United Kingdom